Search research articles
Contact Us
Filters
Showing results (51-60 of 67) with videos related to
Page
of 7
Sort By:
Cancer Research
|
November 13, 2020
Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of <i>ESR1</i>-Mutant Breast Cancer
Michelle M Williams, Nicole S Spoelstra, Spencer Arnesen, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 6, 2024
Cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies
Marie-Anne Goyette, Laura E Stevens, Carolyn R DePinho, et al.
The Journal of Clinical Investigation
|
February 1, 2024
HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial
Zheqi Li, Otto Metzger Filho, Giuseppe Viale, et al.
Biorxiv : the Preprint Server for Biology
|
March 27, 2026
Estrogen receptor-positive cell line xenograft models recapitulate metastatic dissemination and endocrine response of invasive lobular breast carcinoma
Nilgun Tasdemir, Laura Savariau, Julie Scott, et al.
Cell Reports
|
November 21, 2024
ZBTB7A is a modulator of KDM5-driven transcriptional networks in basal breast cancer
Benedetto DiCiaccio, Marco Seehawer, Zheqi Li, et al.
Nature Communications
|
December 2, 2017
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance
Lesley-Ann Martin, Ricardo Ribas, Nikiana Simigdala, et al.
Nature Communications
|
April 20, 2022
ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation
Zheqi Li, Olivia McGinn, Yang Wu, et al.
Breast Cancer Research : BCR
|
January 31, 2024
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer
Filipa Lynce, Laura E Stevens, Zheqi Li, et al.
Cancer Research
|
November 21, 2022
JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
Laura E Stevens, Guillermo Peluffo, Xintao Qiu, et al.
Nature Cancer
|
June 27, 2025
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2<sup>+</sup> breast cancer that limits trastuzumab deruxtecan efficacy
Dong Hu, Xiaoshuang Lyu, Zheqi Li, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 67) with videos related to
Sort By:
Page
of 7
Cancer Research
|
November 13, 2020
Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of <i>ESR1</i>-Mutant Breast Cancer
Michelle M Williams, Nicole S Spoelstra, Spencer Arnesen, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 6, 2024
Cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies
Marie-Anne Goyette, Laura E Stevens, Carolyn R DePinho, et al.
The Journal of Clinical Investigation
|
February 1, 2024
HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial
Zheqi Li, Otto Metzger Filho, Giuseppe Viale, et al.
Biorxiv : the Preprint Server for Biology
|
March 27, 2026
Estrogen receptor-positive cell line xenograft models recapitulate metastatic dissemination and endocrine response of invasive lobular breast carcinoma
Nilgun Tasdemir, Laura Savariau, Julie Scott, et al.
Cell Reports
|
November 21, 2024
ZBTB7A is a modulator of KDM5-driven transcriptional networks in basal breast cancer
Benedetto DiCiaccio, Marco Seehawer, Zheqi Li, et al.
Nature Communications
|
December 2, 2017
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance
Lesley-Ann Martin, Ricardo Ribas, Nikiana Simigdala, et al.
Nature Communications
|
April 20, 2022
ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation
Zheqi Li, Olivia McGinn, Yang Wu, et al.
Breast Cancer Research : BCR
|
January 31, 2024
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer
Filipa Lynce, Laura E Stevens, Zheqi Li, et al.
Cancer Research
|
November 21, 2022
JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
Laura E Stevens, Guillermo Peluffo, Xintao Qiu, et al.
Nature Cancer
|
June 27, 2025
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2<sup>+</sup> breast cancer that limits trastuzumab deruxtecan efficacy
Dong Hu, Xiaoshuang Lyu, Zheqi Li, et al.
Page
of 7